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Evaluation of Patient- and Surgeon-Specific Variations in Patient-Reported
Urinary Outcomes 3 Months After Radical Prostatectomy
From a Statewide Improvement Collaborative
Gregory B. Auffenberg, MD, MS; Ji Qi, MS; Rodney L. Dunn, MS; Susan Linsell, MHSA; Tae Kim, MHSA;
David C. Miller, MD, MPH; Jeffrey Tosoian, MD, MPH; Richard Sarle, MD, MPH; William K. Johnston III, MD;
Eduardo Kleer, MD; Khurshid R. Ghani, MBChB, MS; James Montie, MD; James Peabody, MD
Invited Commentary
IMPORTANCE Understanding variation in patient-reported outcomes following radical

Supplemental content

prostatectomy may inform efforts to reduce morbidity after this procedure.
OBJECTIVE To describe patient-reported urinary outcomes following radical prostatectomy in

the diverse practice settings of a statewide quality improvement program and to explore
whether surgeon-specific variations in observed outcomes persist after accounting for
patient-level factors.
DESIGN, SETTING, AND PARTICIPANTS This prospective population-based cohort study
included 4582 men in the Michigan Urological Surgery Improvement Collaborative who
underwent radical prostatectomy as primary management of localized prostate cancer
between April 2014 and July 2018 and who agreed to complete validated questionnaires
prior to surgery and at 3, 6, and 12 months after surgery. Data were analyzed from 2019 to
June 2019.
EXPOSURES Radical prostatectomy.
MAIN OUTCOMES AND MEASURES Patient- and surgeon-level analyses of patient-reported
urinary function 3 months after radical prostatectomy. Outcomes were measured using
validated questionnaires with results standardized using previously published methods.
Urinary function survey scores are reported on a scale from 0 to 100 with good function
established as a score of 74 or higher.
RESULTS For the 4582 men undergoing radical prostatectomy within the Michigan Urological
Surgery Improvement Collaborative who agreed to complete surveys, mean (SD) age was
63.3 (7.1) years. Survey response rates varied: 3791 of 4582 (83%) responded at baseline,
3282 of 4137 (79%) at 3 months, 2975 of 3770 (79%) at 6 months, and 2213 of 2882 (77%) at
12 months. Mean (SD) urinary function scores were 88.5 (14.3) at baseline, 53.6 (27.5) at 3
months, 68.0 (25.1) at 6 months, and 73.7 (23.0) at 12 months. Regression analysis
demonstrated that older age, lower baseline urinary function score, body mass index
(calculated as weight in kilograms divided by height in meters squared) of 30 or higher,
clinical stage T2 or higher, and lack of bilateral nerve-sparing surgery were associated with a
lower probability of reporting good urinary function 3 months after surgery. When evaluating
patients with good baseline function, the rate at which individual surgeons’ patients reported
good urinary function 3 months after surgery varied broadly (0% to 54.5%; P < .001).
Patients receiving surgery from top-performing surgeons were more likely to report good
3-month function. This finding persisted after accounting for patient risk factors.
CONCLUSIONS AND RELEVANCE In this study, patient- and surgeon-level urinary outcomes
following prostatectomy varied substantially. Documenting surgeon-specific variations after
accounting for patient factors may facilitate identification of surgical factors associated with
superior outcomes.
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adical prostatectomy has long been considered a criterion-standard treatment for prostate cancer. Although this treatment is often curative,1,2 it also carries substantial potential morbidities.3-5 Urinary dysfunction
is a common adverse effect of this procedure.5-10 Up to twothirds of men undergoing prostatectomy report having to use
incontinence pads 2 months after surgery.5 Although some recover continence over time, the interval to regaining urinary
control for most men is variable, and nearly 20% continue to
re p o r t s o m e u r i n a r y i n c o nt i n e n c e 1 5 ye a r s a f te r
prostatectomy.10
Urinary morbidity estimates, made possible through the
collection and analysis of large volumes of patient-reported
outcome (PRO) data, have improved patient and physician understanding of adverse effects associated with prostatectomy. However, to our knowledge, such data have not been analyzed in a way that drives improvement in postsurgical
outcomes. Collection of PRO data across a population with
granular risk adjustment to account for patient-level differences and subsequent comparison across surgeons may present a meaningful use of PRO data to facilitate improvement.
If it is possible to identify surgeons who consistently achieve
superior outcomes despite other factors, there may be opportunities to learn from those surgeons to limit morbidity for
populations of men seeking surgical management of prostate
cancer.
In this context, we evaluated patient-reported urinary
function during the first year after prostatectomy using data
from patients undergoing surgery within the statewide Michigan Urological Surgery Improvement Collaborative (MUSIC).
Patient-reported urinary outcomes were collected at baseline
and at 3, 6, and 12 months after surgery. We also explored patient- and surgeon-specific variation in 3-month urinary outcomes. We evaluated whether there are surgeons who consistently achieve superior outcomes even after accounting for
patient age, body mass index (calculated as weight in kilograms divided by height in meters squared), race, diabetes status, baseline function, prostate-specific antigen (PSA) level,
Gleason score, clinical stage, and receipt of nerve sparing
surgery.

Methods
MUSIC
MUSIC was established in 2011 in partnership with Blue Cross
Blue Shield of Michigan. The quality improvement collaborative currently comprises 44 diverse community and academic urology practices and more than 250 urologists—more
than 90% of the urologists in the state. The collaborative maintains a registry of all patients newly diagnosed with prostate
cancer in participating sites. The registry includes detailed
demographic, laboratory, and clinicopathologic data related to
diagnostic testing, subsequent treatment(s), and outcomes of
treatment. Previous reports have described MUSIC’s data quality-control activities, including annual data audits at each practice and validation analyses based on insurance claims.11,12 Each
MUSIC practice obtained an exemption or approval for collabE2

Key Points
Question Which patient- and surgeon-specific factors are
associated with urinary outcomes 3 months after radical
prostatectomy?
Findings In this cohort study including 4637 men following radical
prostatectomy, there was broad variation in patient-reported
urinary outcomes 3 months after surgery. The percentage of
patients reporting good urinary function at 3 months varied from
0% to 55% across surgeons, and this difference persisted after
accounting for patient factors associated with differences in
urinary outcomes.
Meaning Patient-reported urinary outcomes varied substantially
across surgeons performing radical prostatectomy, and identifying
technical factors associated with superior outcomes may limit
morbidity for patients with prostate cancer.

orative participation from a local institutional review board and
separate institutional review board approval for participation in the MUSIC PRO program. Given the qualityimprovement focus of MUSIC, both the collaborative’s registry and the PRO initiative were deemed exempt from obtaining
informed consent. Every patient was provided with an acknowledgement statement prior to their first survey explaining the purpose of the program and given the choice to opt out
of the program.

MUSIC PRO
MUSIC PRO started data collection in April 2014, and the program has been described elsewhere.13 Participating surgeons
enroll patients undergoing radical prostatectomy to take part
in MUSIC PRO for prospective collection of validated PRO
surveys.
From the establishment of the program through September 2016, MUSIC PRO evaluated outcomes using the Prostate
Quality of Life Survey developed and validated at Memorial
Sloan Kettering Cancer Center, New York, New York.14 From
September 2016 to 2020, MUSIC PRO has used the 26-item Expanded Prostate Cancer Index Composite Short Form questionnaire (EPIC-26) (eAppendix in the Supplement).15 The Memorial Sloan Kettering Cancer Center tool evaluates urinary
function in a 5-question survey where scores range from 0 to
21 and good function is defined as a score of 17 or higher.9 The
EPIC-26 survey assesses urinary function on a scale from 0 to
100 points. In previous work, a crosswalk algorithm has been
developed to standardize results from each survey on a scale
from 0 to 100 points with good function defined as a score of
74 or higher. All results in this study are reported on this 100point scale.16
Each participant was asked to complete a questionnaire
to assess the above outcomes at baseline and at 3, 6, and 12
months after surgery. Surveys were initially distributed via
email and completed online through a web-based platform. For
patients without email access, a paper version was sent with
a self-addressed and stamped return envelope. The MUSIC coordinating center provided practices with tablets for online data
collection in the clinic when feasible. For each survey period,

JAMA Surgery Published online January 20, 2021 (Reprinted)

© 2021 American Medical Association. All rights reserved.

Downloaded From: https://jamanetwork.com/ by a Henry Ford Health System User on 03/08/2021

jamasurgery.com

Evaluation of Variations in Patient-Reported Urinary Outcomes 3 Months After Radical Prostatectomy

an acceptable window for completion was defined, and surveys completed outside of the specified window were excluded from analysis (eg, 3-month surveys were excluded if
not completed between 60 and 120 days after date of surgery) (eFigure in the Supplement). Surveys that were not completed or completed outside of the acceptable window were
excluded from analysis.

Study Cohort
Between April 2014 and July 2018, 4582 men agreed to participate in MUSIC PRO and all were considered eligible for this
analysis. Across Michigan, 95 surgeons from 29 urology practices treated these patients with a median (range; interquartile range) of 21 (1-536; 7-55) patients per surgeon.

Statistical Analysis
Patient-Level Analyses and Development of Risk Strata
Clinical and demographic characteristics were reported for all
MUSIC PRO participants and compared across groups of survey
responders and nonresponders at 3 months using the Wilcoxon
rank sum test for continuous measures and χ2 testing for categorical measures. Urinary function scores were reported for responders at baseline and 3, 6, and 12 months on a scale from 0
to 100 points. We used 3-month urinary function data to fit a multivariable logistic regression model to evaluate factors associated with patients reporting good 3-month urinary function. In
this model, we included variables that have been previously associated with functional outcomes after prostatectomy, including age, body mass index, baseline urinary function score, and
log-transformed preoperative PSA level as continuous covariates and race/ethnicity (defined in the registry based on medical record documentation), diabetes status, biopsy Gleason score,
clinical T stage, surgical approach (open vs robotic-assisted), and
receipt of nerve-sparing surgery as categorical covariates. Men
with missing data for any of the evaluated covariates were not
included in the model. Regression results were used to stratify
patients into risk quintiles based on the predicted probability that
an individual would report a 3-month urinary function score of
74 or higher where individuals in the lowest risk quintile were
most likely to report good urinary function.
Surgeon-Level Analyses
For evaluation of surgeon-level performance, we included surgeons with at least 10 patients reporting a urinary function score
of 74 or higher at baseline who also responded to the 3-month
PRO survey. We determined the percentage of each surgeon’s patients who reported good urinary function both at baseline and
at 3 months to define surgeon-specific variation in outcomes.
From this, we identified a group of top-performing surgeons who
were above the 75th percentile in the overall sample for the percentage of patients reporting good function 3 months after
surgery.
Next, we performed a stratified analysis to evaluate
whether top-performing surgeons demonstrated superior outcomes regardless of patient characteristics or because of favorable patient risk profiles. To do this, we evaluated whether
the percentage of patients reporting good urinary function at
3 months was different for patients receiving surgery from top-
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performing surgeons vs those under the care of the remaining surgeons from the collaborative within each of the patient risk quintiles defined during patient-level regression
analyses.
Finally, in an effort to evaluate if there was an association
between functional outcomes achieved by top-performing surgeons and cancer control, we compared top-performing surgeons with the remaining surgeons across 2 short-term measures of cancer control1: the percentage of patients achieving
a PSA level of less than 0.1 ng/mL (to convert to micrograms
per liter, multiply by 1) within 6 months of surgery and the percentage of patients with organ-confined disease (ie, stage pT2)
and negative surgical margins. Multivariable regression models were fit in this step to account for patient-level covariates
either previously demonstrated to affect these outcomes17,18
or likely to be associated with outcomes, including patient age,
race/ethnicity, body mass index, preoperative PSA level, biopsy Gleason score, and clinical T stage. All statistical testing
was 2-tailed, performed using Statistical Analysis System software, version 9.4 (SAS Institute), and P < .05 was considered
statistically significant.

Results
Of 4582 men enrolled in MUSIC PRO prior to radical prostatectomy, 4137 (median [IQR] age, 63.8 [58.2-68.5] years) were
considered eligible to answer the 3-month survey (ie, were at
least 60 days from the date of their prostatectomy). Of these,
3791 (82.7%) completed a baseline survey and 3282 (79.3%)
completed a 3-month survey. Of the men who responded to
the 3-month survey, 2818 (85.9%) completed surveys within
acceptable proximity to surgery and were included for analysis of 3-month outcomes (eFigure in the Supplement). Table 1
contains demographic information of all individuals in the
analysis, including survey responders and nonresponders.
Compared with men excluded from the 3-month outcome
analysis, those included in the 3-month functional analyses
were older (mean [SD] age of 63.5 [7.0] years vs 62.7 [7.3] years),
more likely to be White (87.8% [2777 of 2818] vs 76.1% [918 of
1319]; P < .001), less likely to have diabetes (11.1% [312 of 2818]
vs 14.4% [190 of 1319]), and had slightly higher baseline urinary function scores (mean [SD] score of 88.9 [13.3] points vs
86.5 [16.8] points). They did not differ across the other characteristics reported in Table 1.
Mean (SD) urinary function scores were 88.5 (14.3) at baseline, 53.6 (27.5) at 3 months, 68.8 (25.1) at 6 months, and 73.7
(23.0) at 12 months (Figure 1). The observed variation in patient scores was greatest at the 3-month time point (median,
interquartile range [IQR]: 52, 31.3-77.4) (Figure 1). Table 2 presents findings from the patient-level multivariable analysis
used to identify factors associated with 3-month urinary outcomes. Older age, body mass index of 30 or higher, and clinical stage T2a or higher were associated with worse 3-month
urinary outcomes, whereas patients with higher baseline urinary function and those who received bilateral nerve-sparing
surgery were more likely to report good function 3 months after surgery.
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Table 1. Patient Characteristics of Entire Michigan Urological Surgery Improvement Collaborative
Patient-Reported Outcome Cohort and Comparison of Characteristics of 3-Month Survey Responders
and Nonresponders or Excluded Responders

Characteristic

No. (%)
Total patients
enrolled

Survey
responders

No. of patients

4137

2818

1319

NA

Age, median (IQR), y

63.8 (58.2-68.5)

64.1 (58.8-68.6)

62.9 (57.3-68.1)

<.001

<25

675 (16.5)

459 (16.4)

216 (16.6)

25-29

1824 (44.5)

1260 (45.0)

564 (43.3)

30-34

1118 (27.3)

738 (26.4)

380 (29.2)

≥35

484 (11.8)

342 (12.2)

142 (10.9)

Survey nonresponders
or excluded respondersa P valueb

Body mass index, mean (SD)c

.21

Race
White

3188 (84.1)

2270 (87.8)

918 (76.1)

African American

508 (13.4)

259 (10.0)

249 (20.6)

Other

95 (2.5)

55 (2.1)

40 (3.3)

502 (12.1)

312 (11.1)

190 (14.4)

.002

91.3 (85.7-100)

91.3 (86.2-100)

89.4 (84.8-100)

.001

6.1 (4.5-8.9)

6.0 (4.5-8.8)

6.2 (4.6-9.1)

.07

6

775 (19.1)

528 (19.2)

247 (19.0)

7

2583 (63.7)

1752 (63.5)

831 (63.9)

8-10

699 (17.2)

477 (17.3)

222 (17.1)

≤T1c

3018 (73.3)

2046 (72.8)

972 (74.2)

≥T2a

1101 (26.7)

763 (27.2)

338 (25.8)

1896 (67.3)

854 (64.7)

Diabetes
Baseline urinary function score,
median (IQR)
Preoperative prostate-specific
antigen level, median (IQR), ng/mL
Biopsy Gleason score

<.001

Abbreviations: IQR, interquartile
range; NA, not applicable.
SI conversion factor: To convert
prostate-specific antigen to
micrograms per liter, multiply by 1.
a

Group of nonresponders includes
men who did not complete the
survey or who completed the
survey outside of the acceptable
time frame (eFigure in the
Supplement).

b

Continuous factors were compared
with the Wilcoxon rank sum test;
categorical factors were compared
with χ2 test.

c

Calculated as weight in kilograms
divided by height in meters
squared.

.97

Clinical T stage

Receiving bilateral nerve-sparing
surgery

2750 (66.5)

A total of 48 surgeons were included in the surgeon-level
analyses. Across these surgeons, the percentage of patients who
reported good urinary function at both baseline and 3 months
varied from 0% to 54.5% (P < .001) (Figure 2). Twelve surgeons
were above the 75th percentile for percentage of patients reporting good 3-month function and these were classified as the topperforming surgeons (Figure 2). Annualized prostatectomy volume did not differ for top-performing surgeons (median [IQR]
cases per year, 28 [18-50]) relative to those in the 3 lower quartiles for outcomes (median [IQR] cases per year: quartile 1, 17 [1429]; P = .07; quartile 2, 30 [17-46]; P = .92; quartile 3, 41 [2652]; P = .58), although there was a nonsignificant difference in
volume (median [IQR] number of prostatectomies) between the
lowest-performing quartile (17 [14-29]) and highestperforming quartile (28 [18-50]) (P = .07).
Within patient risk quintiles, 3-month outcomes were compared based on whether surgery was performed by a topperforming surgeon or another MUSIC surgeon. Patients who
underwent surgery with top-performing surgeons were more
likely to report good urinary function 3 months after surgery
in all risk quintiles (Figure 3).
After adjusting for patient age, body mass index, race/
ethnicity, preoperative PSA, and biopsy Gleason score, the adjusted rate of negative margins in men with pT2 disease was
80.3% (95% CI, 73.1-85.9) among patients who underwent surgery with top-performing surgeons vs an adjusted rate of negative margins of 70.0% (95% CI, 61.3-77.4) among patients of
E4

.36
.11

remaining surgeons (odds ratio, 1.75; 95% CI, 1.31-2.32;
P < .001). After similar adjustments, there were no differences in the percentage of patients with a PSA level of less than
0.1 ng/mL following surgery between patients of topperforming surgeons (89.4%) vs those of remaining surgeons
(87.7%) (odds ratio, 1.18; 95% CI, 0.90-1.54; P = .23).

Discussion
We report urinary function outcomes following radical prostatectomy from a diverse group of community and academic
urology practices in Michigan. Postoperative urinary function outcomes were most substantial 3 months after surgery
with improvement in urinary function scores at 6 and 12
months, indicating continued recovery over the first postoperative year. Regression analyses demonstrated that patient
age, body mass index, preoperative function, clinical T stage,
and receipt of bilateral nerve-sparing surgery were predictors
of whether a patient would report good urinary function 3
months after surgery. Surgeon-specific analyses revealed significant variability across surgeons in how often patients with
good baseline function also reported good function at 3 months.
Top-performing surgeons achieved superior urinary outcomes regardless of patient risk group. An association between surgeon annual case volume and performance quartile
was not observed, although there was a nonsignificant differ-
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Figure 1. Patient-Reported Urinary Function From the Michigan
Urological Surgery Improvement Collaborative Patient-Reported
Outcome Cohort at Baseline and 3, 6, and 12 Months After Surgery

Original Investigation Research

Table 2. Patient-Level Factors Associated With Recovery
of Good Urinary Function at 3 Monthsa

100

Factor

Adjusted odds ratio
(95% CI)

P value

5-y Age increase

0.81 (0.75-0.87)

<.001

Body mass index, mean (SD)b
Urinary function score

80

60

40

<25

1 [Reference]

NA

25-29

0.90 (0.70-1.18)

.45

30-34

0.66 (0.49-0.89)

.01

≥35

0.68 (0.47-0.98)

.04

Race
White

20

0
Baseline

3 mo

6 mo

3759

2818

2293

0.94 (0.67-1.31)

.70

Other

1.24 (0.64-2.43)

.52

12 mo

Diabetes present

0.92 (0.60-1.39)

.69

1788

10-Point increase in baseline urinary
function score

1.12 (1.03-1.21)

.006

Log-transformed prostate-specific
antigen level

0.94 (0.82-1.09)

.41

Time
Respondents, No.

1 [Reference]

African American

Box-plot representation demonstrating distribution of individual scores at each
measured time point. Boxes represent interquartile ranges, midlines represent
median values, and whiskers represent 95% CIs. The dotted line indicates the
threshold of good function, defined as 74 points or higher.

ence in volume between the lowest-performing quartile and
highest-performing quartile. Top-performing surgeons were
also more likely to achieve negative surgical margins among
patients with pT2 disease and had similar rates of patients
achieving a PSA of less than 0.1 ng/mL following surgery, indicating that superior functional outcomes were achieved without an apparent decrease in surgical rates of cancer control.
These findings build on previous reports of PROs following radical prostatectomy.4-8 In 2008, one of the first multiinstitutional prospectively measured investigations of PROs
after prostate cancer treatment demonstrated a substantial decrease in mean urinary function following prostatectomy.5
These results have been consistently reproduced over the last
decade in various cohort studies.6-8 Our current report from
MUSIC PRO confirmed this while adding perspective given data
were captured from more than 90% of urology practices in the
state with both community and academic settings being well
represented. Our patient-level regression also demonstrated
that age, body mass index, baseline function, clinical T stage,
and nerve-sparing surgery were important factors for predicting 3-month outcomes. Knowledge of the factors associated
with outcomes may augment patient risk stratification and
counseling.
To our knowledge, this is the first report of surgeonspecific variation in PRO outcomes following prostatectomy.
We conducted this study in an attempt to use a large and diverse data set to move beyond the documentation of outcomes toward the identification of improvement opportunities. The finding that top-performing surgeons achieved
consistently superior outcomes after accounting for differences in patient risk is important. This serves as evidence
against the hypothesis that top-performing surgeons achieve
better outcomes solely because they have favorable patient
populations. In their landmark article on surgical technique
and bariatric surgery outcomes, the Michigan Bariatric Surgery Collaborative19 demonstrated that surgeon skill is closely

Biopsy Gleason score
6

1 [Reference]

7

0.97 (0.76-1.23)

.79

8-10

0.80 (0.57-1.13)

.20

Clinical T stage
T1c or less

1 [Reference]

T2a or above

0.70 (0.56-0.88)

.002

1.48 (1.19-1.85)

<.001

Bilateral nerve-sparing surgery
received
Abbreviation: NA, not applicable.
a

Estimates are from a multivariable logistic regression model where covariates
were the factors listed in Table 1. Data from 2250 of 2554 three-month survey
responders (88.1%) were included in the model; the remainder were excluded
because of missing data for 1 or more covariates.

b

Calculated as weight in kilograms divided by height in meters squared.

linked to improved postoperative outcomes. It is possible that
there is a yet-to-be delineated relationship between surgical
skill and outcomes following prostatectomy. In light of this,
the ability to reliably identify surgeons who achieve superior
urinary outcomes is significant. If specific techniques used by
top-performing surgeons can be identified, there may be opportunities to share those strategies with other surgeons to improve outcomes for patients undergoing prostatectomy. Ongoing efforts at MUSIC may help evaluate technic al
performance20 and identify techniques that should be avoided
and those that help top-performing surgeons achieve more favorable outcomes. With growing evidence that coaching interventions can improve surgeons’ skill,21-23 there may be an
opportunity to disseminate these techniques via coaching
workshops.
This study has important implications. Prostate cancer remains one of the leading causes of cancer death for men in the
US,24 and radical prostatectomy is considered a criterionstandard, often curative treatment.1 However, as detailed here
and elsewhere, treatment-related morbidity can be significant. The ability to limit morbidities associated with prostatectomy through quality-improvement efforts, such as those
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Figure 2. Surgeon-Specific Outcomes for Recovery of Good Urinary Function 3 Months Postoperatively

Proportion reporting good urinary function

1.0
Top-performing surgeons
0.8

0.6
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0
0

2

4

6

8
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28
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32

34

36

38

40

42

44

46

48

Surgeon

Data included only for men reporting
good baseline function. Surgeons
with fewer than 10 patients reporting
good baseline function were
excluded from analysis.
Top-performing surgeons were
defined as surgeons with percentage
of patients with good 3-month
urinary function above the 75th
percentile for all surgeons.

Figure 3. Comparison of Patient-Reported Good Urinary Function 3 Months Postoperatively
Among Top-Performing Surgeons vs Other Michigan Urological Surgery Improvement
Collaborative Surgeons Within Patient-Specific Risk Quintiles

Patients in surgeon‐specific
cohort reporting good
urinary function 3 mo postoperatively

100
Other MUSIC surgeons
80

Top-performing surgeons
P <.001

60
P <.001

P <.001

P <.001

40
P =.004
20

0
n = 274 n = 140

n = 256 n = 173

n = 242 n = 180

n = 235 n = 190

n = 187 n = 232

Highest risk

Higher risk

Intermediate risk

Lower risk

Lowest risk

Patient risk strata

ongoing in MUSIC, may substantially diminish the risks of prostatectomy for men in need of curative intervention for prostate cancer. Objective identification of surgeons who achieve
better outcomes, as we have done in this analysis, represents
an important first step.
As we work within MUSIC to improve prostatectomy outcomes for men in Michigan, we are actively using these analyses to guide our efforts. We are striving for 75% of men to
achieve social continence within 3 months of surgery and 90%
to reach that mark within 6 months. To achieve this, we have
launched a multidimensional improvement initiative that leverages MUSIC’s infrastructure and the expertise of objectively identified top-performing surgeons. Our efforts include teaching sessions for MUSIC surgeons led by topperforming surgeons to discuss the technical aspects of
prostatectomy, peer-to-peer in-person review of surgical videos, anonymous peer-review of surgical videos, and individualized reports of PROs benchmarked against performance of
other surgeons in the collaborative. As we collect videos and
develop a formal objective process for reviewing videos to
E6

Risk quintiles were derived from a
patient-specific multivariable
regression model.

evaluate surgical quality,20 we are also working to link technical evaluations to PROs. This may help us to identify specific techniques associated with better outcomes. The collaborative nature of MUSIC would in-turn allow for rapid
dissemination of such findings to surgeons in Michigan and
elsewhere. We are hopeful this will represent a path toward a
meaningful reduction in morbidities associated with prostatectomy in Michigan and serve as a model to more broadly improve prostatectomy outcomes.

Limitations
Our analysis had several limitations. First, urinary morbidity
was not the only potential adverse effect of radical prostatectomy. For instance, there are well-documented decreases in
erectile function and other rare but significant sources of morbidity after prostatectomy. Although we fully recognize the importance of limiting all morbidity after radical prostatectomy
and not urinary morbidity alone, we chose to focus our initial
efforts on urinary recovery given its substantial effect on quality of life.25 Second, within the surgeon-specific analyses, the
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inclusion of surgeons with as few as 10 patients reporting good
baseline function included some surgeons in the analysis with
a relatively small sample size by which to evaluate their performance. Although this may have introduced instability to estimates of individual performance, we performed a sensitivity analysis to increase certainty where we only evaluated
surgeons with at least 20 patients in the cohort (27 surgeons
were included in this sensitivity analysis), and the results did
not substantively differ from the primary findings of the overall analysis. Third, as indicated above and as with any surveybased analysis, possible biases may have been introduced because of missing data or survey nonresponse. Although it is
worth recognizing this possible bias, we believe the survey response rate of approximately 80% in all survey periods is sufficient to reduce the effect of limited survey response. The exclusion of 12% of 3-month survey respondents because of
missing data is similarly of note, but relatively unlikely to have
had a major influence on our findings. Additionally, although
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we made an effort to account for patient factors that can clearly
influence outcomes, there is a possibility that unmeasured elements, such as the utilization of postoperative pelvic floor rehabilitation, may have influenced outcomes in a way that we
were unable to account for. Although plausible, we believe it
is unlikely that unmeasured factors would substantially change
our primary findings.

Conclusions
We have detailed urinary function outcomes for men who underwent prostatectomy procedures in Michigan. We reported
substantial patient- and surgeon-level variation in 3-month urinary outcomes. In identifying surgeons whose outcomes consistently exceed those of their peers regardless of patient factors, we have begun to identify a path to improve urinary
outcomes following prostatectomy.
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